



## ASX Announcement

23 November 2020

### Change of Director Interest Notice – Correction

Invion Limited (ASX:IVX) wishes to advise that on 28 October 2020, an Appendix 3Y was lodged for Thian Chew which contained an incorrect date for the date of change to the interests. The correct date should have been 22 October 2020. The updated Change of Directors Interest Notice is attached to this announcement.

#### Investor enquiries

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

#### Media enquires

Brendon Lau

T: 0409 341 613

E: [brendon@vantagepointpartners.com.au](mailto:brendon@vantagepointpartners.com.au)

#### About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by a Sub-Committee of the Board of Invion Limited. For further information please contact [investor@inviongroup.com](mailto:investor@inviongroup.com).

#### About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>INVION LIMITED</b>
<b>ABN</b>	<b>76 094 730 417</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Chiat Thian CHEW
<b>Date of last notice</b>	18 February 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Change to direct holding.
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect holding is Polar Ventures Limited of which Thian Chew is director and beneficiary.
<b>Date of change</b>	22 October 2020
<b>Total No. of securities held prior to change</b>	546,857,721 shares indirectly held. 27,257,615 unlisted share options directly held
<b>Class</b>	Unlisted Share Options
<b>Number acquired</b>	3,537,736 Share options exercisable at \$0.00 each on or before 31 October 2024 (IVXAW).
<b>Number disposed</b>	Nil.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration. Share Options issued following Shareholder Approval at AGM held 21 October 2020.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Total No. of securities held after change</b>	546,857,721 shares indirectly held.  30,795,351 Share options
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Share Options issued following Shareholder Approval at AGM held 21 October 2020.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

+ See chapter 19 for defined terms.